Vanguard Group Inc Clearside Biomedical, Inc. Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,490,796 shares of CLSD stock, worth $3.24 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,490,796
Previous 2,176,316
14.45%
Holding current value
$3.24 Million
Previous $2.55 Million
49.65%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CLSD
# of Institutions
56Shares Held
15.1MCall Options Held
22.7KPut Options Held
200-
Armistice Capital, LLC New York, NY3.96MShares$5.14 Million0.08% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$2.86 Million3.43% of portfolio
-
Carmignac Gestion Paris, I02.13MShares$2.77 Million0.05% of portfolio
-
Black Rock Inc. New York, NY758KShares$985,6930.0% of portfolio
-
Geode Capital Management, LLC Boston, MA642KShares$834,8760.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $78.2M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...